Release and activity of rifampicin from biodegradable polymer formulations

Research output: Contribution to conferenceAbstract

Abstract

Implantation of an indwelling medical device is often required in order to successfully treat a serious medical issue. However, infection of such devices is an ongoing problem, and can occur when microorganisms, predominantly Staphylococcus species, adhere to the device surface1 . Biodegradable polymer drug delivery technology may be of use in some devices as a means of delivering a high local dose of antimicrobial in order to help prevent infection pathogenesis. In this study the broad spectrum antibiotic rifampicin has been formulated with the polymers PLA (Poly(L-Lactide)) and PLGA (Poly(D,L-lactic-co-glycolic acid(65:35)) and the in vitro drug release over 1 week analysed. Based on the release data (Fig. 1A), the PLGA:rifampicin formulations of 50:50 and 60:40 were selected for further analysis. A 4 week drug release study showed that over the examined period >95% of the rifampicin load was released from both formulations, however increasing the ratio of polymer to drug significantly changed the percentage release profile (Fig. 1B). Investigation of antimicrobial activity revealed that both formulations were able to produce consistently large zones of inhibition in disk diffusion assays over the 4 weeks examined, indicating successful bacterial inhibition (Fig. 1C). What this preliminary study has revealed is that rifampicin can be readily released from PLA and PLGA, and that release can be controlled by adjusting the ratio of polymer to drug. It has also shown that the antimicrobial activity of the rifampicin can be retained for at least 4 weeks. Therefore biodegradable polymers may represent a promising material for use in implanted medical devices as a means of delivering a high local concentration of antimicrobial to help prevent infection pathogenesis.

Conference

ConferenceModelling & Experiments in Drug Delivery Systems
CountryUnited Kingdom
CityGlasgow
Period3/09/185/09/18

Fingerprint

Biodegradable polymers
Rifampin
Polymers
Equipment and Supplies
Antibiotics
Drug delivery
Microorganisms
Infection
Pharmaceutical Preparations
Assays
Staphylococcus
Acids
Anti-Bacterial Agents
Technology
polylactic acid-polyglycolic acid copolymer

Keywords

  • indwelling medical device
  • infection
  • biodegradable polymer drug delivery technology
  • antimicrobial

Cite this

Fraser, J., Muangsaen, H., MacLean, M., & McCormick, C. (2018). Release and activity of rifampicin from biodegradable polymer formulations. Abstract from Modelling & Experiments in Drug Delivery Systems, Glasgow, United Kingdom.
Fraser, J. ; Muangsaen, H. ; MacLean, M. ; McCormick, C. / Release and activity of rifampicin from biodegradable polymer formulations. Abstract from Modelling & Experiments in Drug Delivery Systems, Glasgow, United Kingdom.1 p.
@conference{020e70f4363d4b39a4efbcae07f6dd39,
title = "Release and activity of rifampicin from biodegradable polymer formulations",
abstract = "Implantation of an indwelling medical device is often required in order to successfully treat a serious medical issue. However, infection of such devices is an ongoing problem, and can occur when microorganisms, predominantly Staphylococcus species, adhere to the device surface1 . Biodegradable polymer drug delivery technology may be of use in some devices as a means of delivering a high local dose of antimicrobial in order to help prevent infection pathogenesis. In this study the broad spectrum antibiotic rifampicin has been formulated with the polymers PLA (Poly(L-Lactide)) and PLGA (Poly(D,L-lactic-co-glycolic acid(65:35)) and the in vitro drug release over 1 week analysed. Based on the release data (Fig. 1A), the PLGA:rifampicin formulations of 50:50 and 60:40 were selected for further analysis. A 4 week drug release study showed that over the examined period >95{\%} of the rifampicin load was released from both formulations, however increasing the ratio of polymer to drug significantly changed the percentage release profile (Fig. 1B). Investigation of antimicrobial activity revealed that both formulations were able to produce consistently large zones of inhibition in disk diffusion assays over the 4 weeks examined, indicating successful bacterial inhibition (Fig. 1C). What this preliminary study has revealed is that rifampicin can be readily released from PLA and PLGA, and that release can be controlled by adjusting the ratio of polymer to drug. It has also shown that the antimicrobial activity of the rifampicin can be retained for at least 4 weeks. Therefore biodegradable polymers may represent a promising material for use in implanted medical devices as a means of delivering a high local concentration of antimicrobial to help prevent infection pathogenesis.",
keywords = "indwelling medical device, infection, biodegradable polymer drug delivery technology, antimicrobial",
author = "J. Fraser and H. Muangsaen and M. MacLean and C. McCormick",
year = "2018",
month = "9",
day = "4",
language = "English",
note = "Modelling & Experiments in Drug Delivery Systems ; Conference date: 03-09-2018 Through 05-09-2018",

}

Fraser, J, Muangsaen, H, MacLean, M & McCormick, C 2018, 'Release and activity of rifampicin from biodegradable polymer formulations' Modelling & Experiments in Drug Delivery Systems, Glasgow, United Kingdom, 3/09/18 - 5/09/18, .

Release and activity of rifampicin from biodegradable polymer formulations. / Fraser, J.; Muangsaen, H.; MacLean, M.; McCormick, C.

2018. Abstract from Modelling & Experiments in Drug Delivery Systems, Glasgow, United Kingdom.

Research output: Contribution to conferenceAbstract

TY - CONF

T1 - Release and activity of rifampicin from biodegradable polymer formulations

AU - Fraser, J.

AU - Muangsaen, H.

AU - MacLean, M.

AU - McCormick, C.

PY - 2018/9/4

Y1 - 2018/9/4

N2 - Implantation of an indwelling medical device is often required in order to successfully treat a serious medical issue. However, infection of such devices is an ongoing problem, and can occur when microorganisms, predominantly Staphylococcus species, adhere to the device surface1 . Biodegradable polymer drug delivery technology may be of use in some devices as a means of delivering a high local dose of antimicrobial in order to help prevent infection pathogenesis. In this study the broad spectrum antibiotic rifampicin has been formulated with the polymers PLA (Poly(L-Lactide)) and PLGA (Poly(D,L-lactic-co-glycolic acid(65:35)) and the in vitro drug release over 1 week analysed. Based on the release data (Fig. 1A), the PLGA:rifampicin formulations of 50:50 and 60:40 were selected for further analysis. A 4 week drug release study showed that over the examined period >95% of the rifampicin load was released from both formulations, however increasing the ratio of polymer to drug significantly changed the percentage release profile (Fig. 1B). Investigation of antimicrobial activity revealed that both formulations were able to produce consistently large zones of inhibition in disk diffusion assays over the 4 weeks examined, indicating successful bacterial inhibition (Fig. 1C). What this preliminary study has revealed is that rifampicin can be readily released from PLA and PLGA, and that release can be controlled by adjusting the ratio of polymer to drug. It has also shown that the antimicrobial activity of the rifampicin can be retained for at least 4 weeks. Therefore biodegradable polymers may represent a promising material for use in implanted medical devices as a means of delivering a high local concentration of antimicrobial to help prevent infection pathogenesis.

AB - Implantation of an indwelling medical device is often required in order to successfully treat a serious medical issue. However, infection of such devices is an ongoing problem, and can occur when microorganisms, predominantly Staphylococcus species, adhere to the device surface1 . Biodegradable polymer drug delivery technology may be of use in some devices as a means of delivering a high local dose of antimicrobial in order to help prevent infection pathogenesis. In this study the broad spectrum antibiotic rifampicin has been formulated with the polymers PLA (Poly(L-Lactide)) and PLGA (Poly(D,L-lactic-co-glycolic acid(65:35)) and the in vitro drug release over 1 week analysed. Based on the release data (Fig. 1A), the PLGA:rifampicin formulations of 50:50 and 60:40 were selected for further analysis. A 4 week drug release study showed that over the examined period >95% of the rifampicin load was released from both formulations, however increasing the ratio of polymer to drug significantly changed the percentage release profile (Fig. 1B). Investigation of antimicrobial activity revealed that both formulations were able to produce consistently large zones of inhibition in disk diffusion assays over the 4 weeks examined, indicating successful bacterial inhibition (Fig. 1C). What this preliminary study has revealed is that rifampicin can be readily released from PLA and PLGA, and that release can be controlled by adjusting the ratio of polymer to drug. It has also shown that the antimicrobial activity of the rifampicin can be retained for at least 4 weeks. Therefore biodegradable polymers may represent a promising material for use in implanted medical devices as a means of delivering a high local concentration of antimicrobial to help prevent infection pathogenesis.

KW - indwelling medical device

KW - infection

KW - biodegradable polymer drug delivery technology

KW - antimicrobial

UR - https://mi-network.org/2018/04/04/modelling-experiments-in-drug-delivery-systems-medds/

M3 - Abstract

ER -

Fraser J, Muangsaen H, MacLean M, McCormick C. Release and activity of rifampicin from biodegradable polymer formulations. 2018. Abstract from Modelling & Experiments in Drug Delivery Systems, Glasgow, United Kingdom.